stockrow
Saturday 7 November 2026
Export UNCY’s income statement to Excel — free account
Unicycive Therapeutics, Inc.
UNCY Healthcare Biotechnology
Unicycive Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $675,000.00, down 29.0% from fiscal 2022.
- EPS
- +88.5%
- Free cash flow
- +9.77%
Quarter to June 2026, against a year earlier
3.53
0.05
+1.44%
Follow UNCY
Alert me
Unicycive Therapeutics, Inc. (UNCY) P/E ratio
Unicycive Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2023 | 0.0× | — |
| Sep 2022 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BDTX Black Diamond Therapeutics, Inc. compare | n/m |
| LENZ LENZ Therapeutics, Inc. compare | n/m |
| UNCY Unicycive Therapeutics, Inc. | n/m |
| VANI Vivani Medical, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| PMVP PMV Pharmaceuticals, Inc. compare | n/m |
| NRXP NRx Pharmaceuticals, Inc. compare | n/m |
| OKUR OnKure Therapeutics, Inc. compare | n/m |
| VXRT VAXART, INC. compare | 2.8× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)